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Abstract. the aim of this study was to compare the sensitivity 
of the serological level of anti-p53 antibodies in breast cancer 
patients and to correlate its expression level with patient age, 
histological stage and grade of tumor differentiation. total p53 
protein expression (mutant and wild-type) was also determined 
in the breast cancer tissues using immunohistochemistry 
(ihc). the serological levels of mutant p53 expression 
were found to be age-dependent, reaching the highest level 
at 50 years of age. Faint or low detection was observed in 
patients ≤30 years of age. Anti-p53-antibodies were detected 
in patients ≤40 and ≥61 years of age. The serological levels 
of mutant p53 protein were highly detected in all stages of 
breast cancer, including the early stages. however, anti-p53 
antibodies reached a high level of detection only in stage iii 
breast carcinomas. no expression was found in patients with 
benign breast disease. the detection of p53 mutations was 
dependent on the grade of tumor differentiation, achieving the 
highest level in the poorly differentiated breast carcinomas. 
results from ihc were highly correlated with serological p53 
mutational analysis. Our findings indicate that mutant p53 
in serum is a promising novel parameter for the evaluation 
of cellular biology and the prognosis of breast cancer from 
its early stages using blood samples. anti-p53 antibodies 
were demonstrated to be less sensitive in this study. it is also 
possible to use the expression of mutant p53 protein as a 
molecular marker to differentiate benign breast disease from 
breast carcinoma prior to surgery. 
Introduction
among women, breast cancer is the leading cause of cancer-
related mortality and the most common type of cancer 
worldwide (1-3). Breast cancer is the second most common 
cancer in the world, and its incidence is increasing, with a 
total of 1,050,100 cases in 2002 compared to 572,100 in 1980. 
Worldwide, the ratio of mortality to incidence is approxi-
mately 36% (1-3). Breast cancer causes 370,000 annual deaths, 
representing 13.9% of cancer-related deaths in women. it is 
the most prevalent cancer in the world today, with incidence 
rates highest in industrialized countries. While researchers 
are rigorously searching for the etiology of the disease, a more 
sensitive and early detection employing novel biomarkers 
is required for breast cancer patients. presently, there is a 
growing enthusiasm for applying proteomic approaches to the 
identification of serum biomarkers for the early non-invasive 
diagnosis of cancer and the monitoring of tumor progression. 
in this study, we compared the sensitivity of the serological 
level of mutated p53 protein and the level of anti-p53 anti-
bodies with p53 protein expression in breast cancer patients. 
p53 is a multifunctional transcription factor that promotes 
tumor cell death by regulating the expression of genes involved 
in cell cycle control and apoptosis, dna repair and angio-
genesis (4). Mutations or down-regulation of p53 contribute 
to cancer development and progression (4). p53 mutations in 
cancer patients are often associated with poor prognosis (4). 
mutations in the p53 gene, including amino acid substitutions, 
are present in more than 50% of patients with malignant 
tumors. these mutations change the conformational structure 
of p53, which triggers the inhibition of the dna repair mecha-
nisms and induces programmed cell death by apoptosis (5-7). 
The accumulation of inactive p53 protein in cells significantly 
increases the expression of mutant p53 protein with a longer 
half-life (several hours compared to 20 min for wild-type 
p53). therefore, p53 accumulation in tumor tissues is directly 
related to the presence of mutation in p53 protein (8,9).
antibodies to p53 in the sera of cancer patients have been 
reported since 1982 (10). however, the reported antibody 
frequency in cancer has varied widely, ranging from 2.7 to 
31% in different types of cancers. this is in part due to varia-
tions in the assay systems used (11). although the sensitivity 
of p53 antibodies in diagnosis is not high, these antibodies 
are rare in healthy people (12), making anti-p53 antibodies a 
dependable marker for cancer.
We previously reported the presence of p53 antibodies 
in less than 17% of breast cancer patients (13). in the present 
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study, serological expression of mutant p53 protein was 
analyzed in 55 cases of human breast tumors at different 
stages of progression. the results revealed that the level of 
mutant p53 protein in the serum was directly correlated with 
p53 protein accumulation in breast tumor tissues. serological 
levels of mutant p53 protein in breast cancer patients were 
higher in early-stage and poorly differentiated tumors. this 
finding may be important in the detection of breast cancer at 
early stages, and may be used as a diagnostic tool for differ-
entiating benign and malignant breast disease prior to breast 
surgery. 
another critical clinical question is whether anti-p53 anti-
bodies might be used as early markers of incipient tumors in 
high risk populations. in the present study, we demonstrated 
that the level of anti-p53 antibodies is less sensitive than 
mutated p53 protein in serum. Further experiments are neces-
sary in order to determine whether serological mutant p53 
protein may be used as an early marker in breast cancer.
Materials and methods
Patients. Fifty-five patients from Bahía Blanca, Argentina 
with mammary pathology were evaluated at local hospitals 
(sanatorio privado del sur, interzonal dr Jose penna, regional 
Español, Dr Leonidas Lucero, Hospital de la Asociación 
médica). informed consent was obtained from each patient 
prior to enrollment in the study. serum and breast tissue from 
all breast cancer patients were available for analysis. serum 
samples were collected pre-operatively and stored at -20˚C 
until processing. the median age of the patients was 55 years 
(range 28-91 years).
Mutant p53 protein: Serological analysis. the presence of 
p53 mutant protein in serum was quantified employing the 
p53 elisa Kit (mutant-selective) from oncogene research 
products (cambridge, ma, usa). results were expressed in 
o.d. units and were categorized as negative or positive. the 
elisa assay was deemed suitable for the quantitative determi-
nation of mutant p53 protein. The specific antibodies utilized 
in this assay react with an epitope exclusively expressed in 
the recombinant human p53 protein expressed in Escherichia 
coli, and are exposed only in human mutant p53 proteins, not 
in wild-type p53 forms, making the assay mutant-selective. 
eight serum samples from healthy women without breast 
disease or a family history of breast cancer were utilized in 
the serologic assays as negative controls. 
Anti-p53 antibodies using the ELISA assay. p53 auto-anti-
bodies were quantified in serum employing the p53 ELISAPlus 
(autoantibody) kit (oncogene research products). the kit was 
designed to measure circulating antibodies to p53 in human 
serum samples. control serum provided by the manufacturer 
was employed. the results were expressed in o.d. units and 
were categorized as negative or positive.
Histology. human breast tumor sections (5 µm) were cut from 
formalin-fixed paraffin-embedded tissues and stained with 
H&E for histological evaluation. Nuclear grade was defined 
as grades i-iii according to previously established criteria 
(14,15). Histological classification and the nuclear grade were 
determined by a medical pathologist. a duplicate of each 
tissue was cut in order to analyze the total expression of p53 
protein using immunohistochemistry (ihc).
Immunohistochemistry. tumor cell staining for p53 
protein was performed using mouse monoclonal do-1 
antibody (oncogene research products). all sections were 
de-paraffinized in xylene, dehydrated through a graded 
series of alcohols and washed in phosphate-buffered saline. 
this buffer was used for all subsequent washes. ihc using 
the streptavidin-biotin-peroxidase method was performed 
on paraffin-embedded tissues using the anti-p53 mouse 
monoclonal antibody do-1 (diluted 1:100), which recognizes 
the n-terminus of the human p53 protein (amino acids 21-23). 
in addition, the antibody reacted with wild-type p53 and 
with numerous mutant p53 proteins. in order to perform a 
semi-quantitative assessment, the ihc results were scored. 
nuclear staining in >10% of the tumor cells was interpreted 
as positive: +, 10-25%; ++, 25-50%; and +++, 50-100% of 
nuclear staining.
Statistical analysis. the frequency of p53 values at the 
cut-off and the frequency of p53 values below the cut-off was 
compared to the different parameters by the χ2 test (t-test).
Results
Age-dependent mutated p53 protein expression. Fig. 1 shows 
the elisa results illustrating the age-dependent correlation 
of the serological level of mutant p53 protein (black columns) 
and anti-p53 antibodies (hatched columns) in 55 patients 
with breast malignancies. the total p53 protein expression in 
breast tissue (white columns) determined using ihc is also 
shown. mutated p53 protein levels were detected in patients 
of all ages, but were highly detected in patients ≥61 years of 
age (75% positivity at an age range of 61-70 and 62% at an 
age range of 71-80 years). a similar sensitivity (75% at an 
age range of 61-70 years and 60% at ≥71 years of age) was 
observed for the total p53 protein expression in breast tissue 
by ihc. in addition, the levels of anti-p53 antibodies were 
higher in patients in the age range of 61-70 years (75% of 
positivity). This sensitivity decreased (33%) in patients ≥71 
years of age, probably due to immune system depression and 
the lower level of antibody synthesis at this age.
Notably, at the age range of 41-50 years, the sensitivity of 
mutant protein detection in serum was higher compared to 
the total p53 protein expression in breast tissues (58 and 36%, 
respectively). however, anti-p53 antibodies were practically 
not detected at that age range (only 1% of the total number 
of patients). it is now important to ascertain why the immune 
system did not respond to the increased level of serological 
mutant p53 protein. there are several explanations for this 
discrepancy, including one which suggests that mutant p53 
protein conformational structures are ‘hidden’ to the immune 
system, which does not recognize the foreign epitopes in 
the new p53 mutated protein. Further molecular and genetic 
analysis is necessary to prove this hypothesis.
in the age range of 51-60 years, the sensitivity of 
serological mutant p53 detection was lower in comparison 
with the total p53 protein expression in breast tissues (33 and 
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60%, respectively). anti-p53 antibody sensitivity was again 
low (13%) in this age range. the elisa kit for the detection 
of mutant p53 protein in serum is designed specifically against 
an epitope present in the mutant p53 protein, and did not 
recognize the wild-type form. however, the antibody employed 
in the ihc recognized both forms of p53 protein, mutated and 
wild-type. this is likely the reason for the observed higher 
levels of p53 protein in breast tissues compared to the level 
of mutated p53 protein in serum. the wild-type p53 form 
has a shorter half-life compared to the mutated form. it is 
believed that menopausal breast cancer patients (51-60 years) 
have accumulated a higher level of the wild-type p53 form. 
in order to demonstrate this hypothesis, mutational analysis 
by sequencing of the whole p53 gene and a correlation of the 
presence of point mutations with hormonal changes during 
the menopausal period must be carried out. similar results 
were observed in patients <40 years of age. In the age range 
of 31-40 years, IHC was the most sensitive technique for 
the detection of the accumulation of p53 protein, followed 
by mutant p53 protein in serum (60 and 40%, respectively). 
Notably, the levels of anti-p53 antibodies were high (40%) in 
this age range. one possible explanation for this observation is 
possibly that the immunological system of patients <40 years 
of age is more sensitive to the presence of foreign or mutated 
proteins, thus stimulating antibody synthesis, compared to 
patients >70 years of age, who are less susceptible. 
Histology-dependent curve and p53 protein expression. Fig. 2 
shows the number of cases (% with respect to the total number 
of patients) positive for the presence of mutant p53 protein 
in serum (black column) or for total p53 protein expression 
by ihc (white column) as well as anti-p53 antibody levels 
(hatched column) in samples from 55 patients with different 
stages of breast carcinoma and in 8 serum samples from 
healthy women, used as negative controls. in this study, we 
analyzed 6 patients with benign disease, 2 patients with ductal 
carcinoma in situ (dcis), 19 patients with invasive ductal 
carcinoma (idc) stage i, 7 patients with idc stage ii, 17 
patients with idc stage iii, 1 patient with phylloides tumor 
and 3 patients still undiagnosed at the time of publishing. 
in patients with benign disease, mutant p53 protein was not 
detected in serum (Fig. 2). detection of anti-p53 antibodies 
and p53 protein expression in breast tissue was also negative 
in these patients. total p53 protein expression was detected 
in 1 of 2 patients with dcis (Fig. 2), indicating that 50% of 
dcis patients showed positive expression of p53 by ihc, but 
none were positive for the presence of mutant p53 protein 
in their serum (Fig. 2). Further analysis employing a higher 
number of patients with dcis is needed to reach a conclusion 
concerning the expression of p53 mutations.
among the breast cancer patients with idc stage i, 12 of 
19 patients (63%) were positive for the mutant p53 protein in 
serum. similar results were obtained from the ihc (11/19, 58% 
Figure 1. age-dependent p53 analysis in breast cancer patients. the graph represents age-dependent p53 expression in the different assays performed. Black 
columns indicate the percent of patients expressing mutant p53 protein in serum with respect to the total number of patients. White columns represent the percent 
of positive cases expressing p53 protein in breast tissue by ihc. the hatched columns represent the percent of positive cases demonstrating the presence of 
anti-p53 antibodies in serum samples.
Figure 2. tumor grade-dependent p53 protein expression. the graph represents the number of cases positive for p53 mutated protein expression using elisa 
(black columns), anti-p53 antibodies (hatched columns) and total p53 protein expression in breast tissue by ihc (white columns) in healthy, benign carcinoma 
in situ (dcis) patients and in patients with invasive ductal carcinoma (idc) stages i, ii and iii.
BaloGh et al:  p53 protein at early staGes in Breast cancer patients360
of patients). however, the presence of anti-p53 antibodies was 
lower (6/19, 32% of patients) (Fig. 2). among the breast cancer 
patients with idc stage ii, 5 of 7 patients (71%) were positive 
for mutant p53 in serum. the same results were obtained using 
ihc (5/7, 71% of patients). nonetheless, a very low sensitivity 
was found for the detection of anti-p53 antibodies (1/7, 14% of 
patients). among breast cancer patients with idc stage iii, 9 of 
17 patients (53%) were positive for mutant p53 protein in serum, 
11 of 17 (65%) were positive for total p53 protein expression in 
breast tissues by IHC, and 8 of 17 (47%) exhibited high levels 
of anti-p53 antibodies in their serum samples. 
the present data clearly demonstrate that mutant p53 protein 
expression in breast cancer is stage-dependent. agreement was 
found in the results upon comparing the three molecular biology 
techniques employed in this study. all techniques detected 
mutations in p53 in idc from stage i to iii, but at a different 
sensitivity. anti-p53 antibodies were highest in patients with 
idc stage iii; however they were also detected during the early 
stages of the disease. these results suggest that serological 
expression of mutant p53 protein is a more sensitive technique 
than anti-p53 antibodies for detecting p53 alterations in breast 
cancer, particularly during the early stages of the disease. 
Grade of tumor differentiation and expression of p53 muta-
tions in breast cancer patients. to determine whether the 
grade of tumor differentiation affects the detection of p53 
mutations, we analyzed 55 patients with poor, semi- and 
well-differentiated breast carcinomas (Fig. 3). in patients with 
poorly differentiated breast carcinomas, we found mutated p53 
protein in serum in 7 of 13 patients (63.64%), while 8 of 13 
(72.73%) exhibited total p53 protein expression using ihc. at 
the semi-differentiated level, 8 of 24 patients (33.33%) showed 
the presence of p53-auto-antibodies, 13 of 24 (54.17%) showed 
mutant p53 protein, and 14 of 24 (58.33%) were positive for the 
presence of p53 protein by ihc (Fig. 3). in well-differentiated 
tumors, 5 of 8 patients (62.50%) showed mutant p53 protein 
expression in serum by elisa and in breast tumor tissues 
by ihc (Fig. 3). these results indicate that poorly differenti-
ated breast tumors can be identified by detecting p53 protein 
expression using IHC. No statistically significant differences 
were found in the detection of mutant p53 in serum among the 
poor, semi- or well-differentiated breast carcinomas. however, 
the sensitivity of anti-p53 antibody detection was lower than 
that of mutant p53 protein in serum.
Discussion
the development of molecular markers is required to improve 
the diagnosis and assessment of tumor progression in breast 
cancer patients. mutations in the p53 tumor suppressor gene, 
as well as overexpression of serum p53 antibodies and p53 
protein in tumor tissues, have been encountered in a variety 
of human malignancies (16). the p53 antibody was originally 
described in 1982 by crawford et al (17) in the serum of 9% 
of breast cancer patients using Western blot analysis. more 
than 15 studies were performed by soussi et al using elisa 
in breast cancer (16). the frequency of the p53 antibody in 
breast cancer ranged from 15 to 20%. however, the majority 
of these studies were performed in european countries or in 
the us. no studies have been performed in south america or 
in argentina, where the frequency of breast cancer is similar 
or slightly lower than that observed in the studies conducted.
overexpression of mutant p53 protein in breast cancer 
patients has usually been evaluated in tumor tissue with 
immunohistochemical staining; however, a serum assay for 
p53 oncoproteins using elisa can be performed easily and 
repeatedly due to its minimal invasiveness compared with 
assays using tissue materials (18,19). in the present study, the 
median serum level of mutant p53 protein in patients with 
IDC was significantly different (26 of 43, 60.45%) (p<0.001) 
compared to the controls. 
our results are well correlated with those of studies 
performed in cervical carcinomas by sobti et al (20), who 
detected p53 mutant protein in serum from 61.5% patients 
with invasive cervical carcinoma (20). in addition, oh et al 
(21) recently demonstrated similar results. however, there 
have been few results involving breast cancer. micelli et al 
(22) demonstrated the presence of mutant p53 protein in serum 
in 23% of breast cancer patients, and showed a 100% mutant 
p53 specificity employing 20 healthy controls (22). 
in the present study, mutant p53 protein was predomi-
nantly detected in serum from idc patients with the early 
stages of the disease: 12/19 (63.15%) in stage i (p<0.0001), 
and 5/6 (83.33%) in stage ii (p<0.0001). it was maintained at 
a high level in late stages: 8/16 (50%) of patients in stage iii. 
The specificity of mutant p53 protein detection was 100%, 
since it was found to be negative in the serum of normal 
control patients, and was also negative in patients with benign 
diseases (0/6, 0%). in this study, we observed the expression 
of p53 protein using ihc in 1 of 2 patients with dcis. Further 
analyses are needed to demonstrate the sensitivity of p53 
mutation detection in the serum of patients with dcis.
the presence of mutant p53 protein in serum and p53 
accumulation in tissue was correlated with poorly differentiated 
tumors in patients with IDC (63.64 and 72.73%, respectively; 
p<0.005) compared to those with well-differentiated 
tumors. several studies have demonstrated the presence of 
p53-accumulated protein in breast cancer by ihc. al-moundhri 
Figure 3. p53 expression and tumor differentiation-dependent curve in breast 
cancer patients. the graph shows the percent of positive cases detected in all 
the assays at different grades of tumor differentiation: poor, semi- and well-
differentiated. the level of anti-p53 antibodies, mutant p53 protein in serum 
and expression of total p53 protein in breast tissues by ihc is indicated. open 
circles, poor or low differentiated; black squares, semi-differentiated; open 
triangles, well-differentiated breast carcinomas.
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et al (23) found p53 overexpression in 41.7% of breast tumors. 
they also reported that the p53 accumulation was related to 
poor differentiation in human breast cancer (23). 
expression of conformational altered protein induces an 
immune response, thus leading to the presence of circulating 
anti-p53 antibodies in cancer patients (24). Trivers et al (25) 
used an anti-p53 antibody as a molecular marker and found 
a great level of anti-p53 antibody among five workers occu-
pationally exposed to vinyl chloride, who later developed 
angiosarcoma of the liver (25). 
however, in the present study, the level of anti-p53 anti-
bodies demonstrated low sensitivity in breast cancer patients. 
Its level was higher (47%) in advanced breast disease in 
patients with IDC stage III. No statistically significant differ-
ences have been found in the expression of p53 antibodies and 
the grade of tumor differentiation. We found a high reactivity 
in patients ≤40 and ≥61 years of age, reaching similar levels 
of serological mutant p53 protein in patients at those ages.
recently, it was reported that tp53 and Kras mutation 
detection in the plasma of healthy subjects was associated 
with environmental exposure to carcinogenic agents (26). 
these observations have implications for monitoring the 
early stages of bladder cancer development. in another report, 
analyses were performed to calculate the association between 
the prevalence of positivity for the p53 antibody or mutant-p53 
antigen with accumulative vinyl chloride exposure in a popu-
lation of healthy workers (27). the results from these studies 
demonstrate the utility of the tp53 mutation in a simple 
blood sample as a molecular marker to determine a minimum 
threshold for the effects of exposure to carcinogens. 
in conclusion, mutant p53 protein from serum was elevated 
in invasive breast carcinomas, with a strong correlation with 
p53-accumulation detected by ihc. these data strongly 
indicate that the detection of mutant p53 in serum and p53 accu-
mulation in breast tissue are well correlated, and both tests are 
sensitive and specific for invasive ductal breast carcinomas. A 
prospective study with a large sample size is warranted, as the 
presence of mutant p53 protein in serum is potentially useful 
as a biological marker of breast carcinoma, particularly for the 
prediction of prognosis and in follow-up after treatment.
Our findings indicate that mutant p53 in serum is a prom-
ising novel parameter for the evaluation of cellular biology 
and the prognosis of breast cancer using blood samples, thus 
avoiding surgery. the presence of mutant p53 protein in serum 
is potentially an important tool for discerning benign disease 
prior to performing breast surgery. 
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